From a study that analyzed the therapeutic dilemma of treating acute leukemia (AL) during pregnancy and the delicate balance of improving maternal and fetal outcomes, investigators determined that ...
Patients undergoing intensive chemotherapy for acute myeloid leukemia are routinely treated with multiple antibiotics to prevent infection, a practice that new research from Texas A&M University shows ...
New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.
Acute Myeloid Leukemia is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally. -With relapse rates as high as 50%, routine measurable residual disease (MRD) ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer.
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo ...
Seeley was just weeks old when she was diagnosed with acute myeloid leukemia, a rare and aggressive blood and bone marrow cancer.
InvestorsHub on MSN
Aptevo shares drop despite encouraging AML trial results
Aptevo Therapeutics Inc. (NASDAQ:APVO) shares plunged about 18% on Tuesday even after the company reported promising interim clinical results for its acute myeloid leukemia (AML) treatment candidate, ...
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutic ...
Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...
Cullinan Therapeutics (NASDAQ:CGEM) executives highlighted upcoming clinical milestones for the company’s two high-priority T-cell engager programs during remarks at the 46th Annual TD Cowen ...
Ashlie Hillius' son Levi, 5, was over the moon when he noticed that he was almost home ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results